Bispecific IgG Antibodies as T Cell Engagers for Cancer Treatment

ChangeBridge: EPO Bulletin - Peptides (C07K)

Published March 25th, 2026

Detected April 1st, 2026

Summary

The European Patent Office published patent application EP3470431A1 for Merus B.V., covering bispecific IgG antibodies engineered as T cell engagers for cancer treatment. The patent, filed by inventors Bakker, Van Loo, and Logtenberg, is classified under C07K 16/28 and designates 19 European states including major markets such as DE, FR, GB, IT, and NL.

View original document View source feed page

What changed

EPO published patent EP3470431A1 titled 'Bispecific IgG Antibodies as T Cell Engagers' filed by Merus B.V., a Dutch biotechnology company. The invention relates to bispecific antibodies designed to engage T cells against cancer cells, with the application classified under IPC C07K 16/28. The patent designates 19 European contracting states covering major EU pharmaceutical markets.\n\nCompliance officers and legal teams at pharmaceutical and biotechnology companies should log this patent in their IP monitoring systems to assess potential freedom-to-operate implications for similar bispecific antibody development programs. No immediate compliance action is required; this is a routine patent publication notice. Patent holders gain exclusive rights in designated EPO member states upon grant, which could affect competitive positioning in the bispecific antibody space.

Source document (simplified)

← EPO Patent Bulletin

BISPECIFIC IGG ANTIBODIES AS T CELL ENGAGERS

Publication EP3470431A1 Kind: A1 Mar 25, 2026

Applicants

Merus B.V.

Inventors

Bakker, Alexander Berthold Hendrik, Van Loo, Pieter Fokko, Logtenberg, Ton

IPC Classifications

C07K 16/28 20060101AFI20190313BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →